Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim prophylaxis for chemotherapy-induced neutropenia in children with rhabdomyosarcoma or Ewing's sarcoma
ChiCTR1900022249Phase 4Not yet recruiting
- Sponsor
- Capital Medical University, Beijing Children's Hospital
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in chemotherapy-induced neutropenia (CIN), sponsored by Capital Medical University, Beijing Children's Hospital. Primary endpoint: Incidence of grade 3 or higher neutropenia. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on ChiCTR1900022249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022249.